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Abstract

Fallahi, Fahimeh. M.S. Department of Pharmacology &Toxicology, Wright
State University, 2012. Gold Nanoparticles in Central Nervous System of
Mice: Localization and Inflammatory Markers.

Gold nanoparticles (GNPs) possess unique physicochemical properties that may
facilitate entry into the central nervous system (CNS) where they may act therapeutically.
There is little information on biodistribution or inflammatory effects of GNPs in specific
brain regions. Brain Localization and neuroinflammatory response to citrate-capped
spherical GNP (10 nm) was determined 24 hours after intravenous (IV) injection in male
C57Bl mice. A known inflammogen, lipopolysaccharide (LPS, 2 mg kg-1, SC), was tested
as a positive control supplement. Aggregation of GNPs was measured using various
Phosphate-Buffered Saline (PBS) concentrations (10, 1, 0.1, 0.01 X) to determine the
optimal buffer concentration to maintain GNP solubility. 0.01 X PBS was used in all
studies, since it produced the least amount of GNP aggregation. The next experiment
verified entry of GNPs into the CNS. Mice were injected IV (200 µg mL-1 10 nm GNP in
0.01 X PBS) via the tail vein. After 24 hours mice were euthanized (with 130 mg ml-1
Euthasol),

and

perfused

transcardially

(with

2%

glutaraldehyde

and

2%

paraformaldehyde), then brains were removed. GNP concentrations were measured using
inductively coupled plasma mass spectrometry in whole brain homogenates. To
specifically localize accumulation of GNPs in brain, septum, caudate, hippocampus,
hypothalamus, cortex, frontal cortex, and spinal cord regions were micro dissected.
iii

Hypothalamus, hippocampus, and septum had the highest GNP levels (6.7, 6.2, and 4.6
µg Au g-1 tissue respectively). To evaluate brain inflammation, we used q-PCR analysis
of frozen brain regions for study of pro-inflammatory mediators, Leukemia inhibitory
factor (LIF), CC chemokine ligand 2 (CCL2) and Interleukine-1 β (IL-1β). GNPs did not
affect cytokine/chemokine expression in cortex, frontal cortex or hippocampus. LPS
(positive control), as expected, caused a marked (100-fold) increase in the same
cytokines. Results show that GNPs enter brain and concentrate in specific regions
without eliciting an inflammatory response. Data raise the possibility of usefulness of
GNPs in drug delivery and therapeutic treatment of CNS diseases.
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I. INTRODUCTION
I.1. Nanomaterials:
Nanomaterials are defined as materials having at least one dimension within the range of
1-100 nm. They are produced from manipulation of material at the nanoscale.
Engineering of size at this scale creates new materials with novel functionality and
physicochemical properties. The various forms of nanomaterials include nanotubes,
nanowires, fullerene derivatives (buckyballs), and quantum dots. The nanoparticles have
obtained considerable recognition and have contributed to the improvement of new
analytical apparatus used in either physical or life sciences (Cui & Gao, 2005; Wu &
Bruchez, 2004). The United States Air Force is interested in nanomaterials due to their
possible application in multiple advanced systems used as electronics, sensors, and
energy production (Hussain, et al., 2006). Organelle or DNA damage, oxidative stress,
apoptosis (programmed cell death), mutagenesis, and protein up/down regulation are
destructive effects of the interaction of nanoparticles and cellular components such as the
membrane, mitochondria, or nuclei (Unfried, et al., 2007; Aillon, et al., 2009; Jia, et al.,
2009; Pan, et al., 2009). Since 2000, a growing number of researchers have targeted the
effects of nanomaterials on biological interfaces and environmental health. One of the
main objectives of research was to comprehend the relationship of size, shape, and
surface chemistry to interaction of variety of nanomaterials with biological systems
1

(Lewinski, et al., 2008). Due to diverse variable component such as physical and
chemical properties of the nanoparticles, cell variety, dosing, and the type of biochemical
test used, the outcome is not standardized and therefore inconclusive. An important
characteristic of nanoparticles is protein adsorption which facilitates passage of
nanomaterial via receptor-mediated endocytosis (Conner and Schmid, 2003). Research on
the cellular effects of nanomaterials in vitro has been the predominant method; it is
imperative that to study in vivo effects of nanomaterials (Fischer and Chan, 2007) as
well.

Figure I.1: A Size Comparison of Biological Systems and Nanoparticles (Modified from
Kattumuri, et al., 2006).
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I.2. Gold nanoparticles:
Gold nanoparticles (GNPs) possess a multitude of unique characteristics such as stability
and distinct optical properties that make them useful for biological imaging by electron
microscopy and chemical sensing (Lasagna-Reeves, et al., 2010). Depending on size,
charge, shape, and dose, the GNPs have different properties. Due to their straight forward
preparation and the selective adsorption to recognition molecules GNPs have been
successfully used as a basis for drug delivery (Guerrero, et al., 2010). In addition, their
ability to intensely react to time-varying magnetic field, allows for their use in thermal
therapy to targeted bodies and ultimately for treatment of cancer, degenerative disorders,
and other chronic diseases (Lasagna-Reeves, et al., 2010). Bulk gold is well known to be
“safe” and chemically inert, and gold-based compounds have been used in the clinic as
anti-inflammatory agents to treat rheumatoid arthritis (Finkelstein, et al., 1976). Gold
microparticles have been successfully used in local radioisotope cancer therapy (Metz, et
al., 1982). In addition, gold nanoparticles are good candidates for photothermal therapy
and imaging agents for in vivo studies (Turner, et al., 2008).

3

I.3. Toxicity of Gold Nanoparticles:
Distinctive characteristics of GNPs have created technological and scientific interests. It
is vital to understand GNPs potential toxicity and health impact prior to their application
in clinical settings (Alkilany, et al., 2010). Functionalization of nanoparticles with
polyethylene glycol (PEG) will increase their circulatory time by preventing their blood
protein adsorption which is useful in treatment (Eghtedari, et al., 2009 and von Maltzahn,
et al., 2009). It is important to consider local and systemic toxicity of GNPs in drug
delivery (Lasagna-Reeves, et al., 2010). Many studies verify the nontoxic nature of
GNPs. An MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is
a colorimetric metabolic assay and is a “gold standard for cytotoxicity. It measures the
enzymatic activity of cellular mitochondria and index of cellular activity (Marquis, et al.,
2009). An MTT colorimetric assay using a human leukemia cell line indicated that 4, 12,
and 18 nm gold nanospheres and capping agents (citrate, cysteine, glucose, biotin, and
cetyltrimethylammonium bromide) were nontoxic (Connor, et al., 2005). Likewise,
citrate-capped gold nanospheres of 10 nm were not toxic and did not induce activation or
change phenotype of dendritic cells of human immune system (Villiers, et al., 2010).
Comparable results were obtained using nanospheres of 3.5 nm on immune system cell
line (Shukla, et al., 2005). 3.5 nm GNPs endocytosed did not reduce reactive oxygen
species level or cause toxicity (Alkilany, et al., 2010). Other groups found contradictory
results (Alkilany, et al., 2010) i.e. 2 nm cationic gold nanospheres appeared toxic at
4

certain doses, but at the same concentration with the same cell line with the negatively
charged surface were nontoxic (Goodman, et al., 2004). This was due to interaction of
cationic GNPs and disruption of negatively charged cellular membrane (Goodman, et al.,
2004). 1.4 nm gold nanospheres caused necrosis, mitochondrial damage, oxidative stress
on all cell lines, but no cellular damage resulted from 15 nm gold nanospheres having
same surface properties. This was indicative of size-dependent toxicity of GNPs (Pan, et
al., 2009). The chemical reactivity exhibited by GNPs smaller than 2 nm was not
observed with larger sizes (Turner, et al., 2008). These contradictions are possibly related
to variation of toxicity assays, cell lines, and physicochemical properties of nanoparticles.
In addition, due to difference in dosing parameters and exposure time, it is difficult to
make comparisons (Alkilany, et al., 2010). There are many commercial kits available for
quantifying cellular health. Some examples include ROS (Reactive Oxygen Specie)
assays for monitoring oxidative stress through ROS level, real-time polymerase chain
reaction amplification and DNA micro- array analysis which determine level of gene
expression (Marquis, et al., 2009). Intracellular oxidative stress is quantified through
GSH (Glutathione) depletion, MDA (3,4-Methylenedioxyamphetamine) production, SOD
(Superoxide dismutases) inhibition, and ROS generation which are indicatives of
cytotoxicity. GSH is a critical antioxidant which stabilizes cellular redox status by
preventing lipid peroxidation of radicals. MDA deletion is a method of measuring lipid
peroxidation (Wu, et al., 2011). ROS and oxidative stress have shown to be a good
indicator for assessment of cellular cytotoxicity by nanoparticles (Xia, et al., 2006).
5

I.4. Neurodegenerative Diseases:
The mechanisms of neurodegenerative diseases have not been fully understood. In
neurodegeneration, neurons, microglia, and astroglia may be the targets or the source of
cytokines and chemokines. Microglia and astroglia activation, immune response, and
inflammatory response (i.e. up-regulation of tumor necrosis factor α, interleukin-1β, βchemokine monocyte chemoattractant protein-1) are linked with neurodegenerative
diseases such as Alzheimer's and Parkinson's diseases as well as Multiple Sclerosis. It is
not clear whether these responses initiate the disease or they are just body’s response to it
(O'Callaghan, et al., 2008; Little, et al., 2002). Parkinson’s disease is a neurodegenerative
disease of the central nervous system. Specifically neurodegeneration of the nigrostriatal
tract results in death of dopamine-generating neurons in the substantia-nigra, loss of
striatal tyrosine hydroxylase containing nerve endings, and reduced striatal dopamine
production causing irregular motor symptoms (Pardridge, 2005). In neurodegenerative
diseases such as Parkinson's disease, Hallervorden-Spatz syndrome, and Alzheimer's
disease lesion, which leads to loss of function or structure, plays a crucial role in
causation of diseases (Tansey, et al., 2008).

6

I.5. Neuroinflammatory Response:
I.5.1. Cytokines:
Cytokines are small short acting proteinaceous messenger molecules that are used in cell
communications. They play an important role in mediating inflammatory and immune
response. Specific cytokines participate in brain signaling and are involved in production
of neurochemical, neuroendocrine, neuroimmune, and behavioral changes of the normal
brain and may become highly elevated in certain pathological disorders. These diverse
groups of proteins act in a cascade, regulating the immune and inflammatory response as
well as certain pathological and physiological conditions. Cytokines are pleotropic and
have multiple overlapping biological activities. For example IL-1 may produce
immunological effect (production of IL-1, IL-6, and TNFα), neurochemical effect,
neuroendocrine effect (increase in hypothalamic- pituitary-adrenal (HPA) activity), and
behavioral effect (increase sleep, decrease appetite and sexual drive). It is also known
that different cytokines may produce identical biological effects. Upregulation and
downregulation of cytokines is highly dependent on stimulation by preceding cytokines
(Kronfol & Remick, 2000). Conventionally inflammation outside of CNS involves
production of proinflammatory cytokines and chemokines by neutrophils and
macrophages, activation of complement proteins and production of reactive oxygen
species (ROS) at the site of injury. In brain inflammation microglia and astrocytes are not
only source of proinflammatory cytokines but also targets of it (O'Callaghan et al., 2008).
7

Additionally under certain conditions, neurons have the ability to produce cytokines
(Freidin, et al., 1992). IL-1 has been localized in hippocampus and specific hypothalamic
areas. Additionally, hypothalamus has been identified as a specific region for IL-1
immunoreactive nerve in human brain (Breder, et al., 1988). There are also extensive
immunoreactive regions of TNF and other cytokines in the murine brain (Breder, et al.,
1993). Low levels of constitutive expression of certain cytokines have been detected in
brain’s blood vessel in addition to the expression of cytokines in response to stimuli
(Licinio, et al., 1998). Five major hypothesized mechanisms of cytokine signaling in
brain are as follows:
1. Passive transport through circumventricular sites or damaged blood–brain barrier
(BBB)
2. Activation of brain’s endothelial cells and inducing production of secondary
messengers like nitric oxide or prostaglandins that can diffuse through BBB
3. Active carrier mediated transport
4. Activation of afferent nerves of autonomic nervous system at periphery
5. Activation of afferent vagus nerves (Watkins, et al., 1995).
Leukemia inhibitory factor (LIF) is a multifunctional glycoprotein cytokine of the
interleukin 6 (IL-6) family. It binds to gp190 (its specific receptor LIFR-a) and gp130
(common to all members of IL-6 family of cytokines) receptors and signals through JAKSTAT (janus-kinase signal transducer and activator of transcription) and MAPK (mitogen
activated protein kinase) pathways. The activation is terminated by SOCS (suppressor-of
8

cytokine signaling) and PIAS (protein inhibitors of activated STAT) proteins. Some of its
more common functions are pro and anti-inflammatory, hematopoietic (regulation of
differentiation and proliferation) and neuronal actions, inhibition of cell growth and
differentiation,

and

endocrine

activity

in

hypothalamic-pituitary-adrenal

axis

(neuroimmune mediating effects), bone cell remodeling and metabolism, energy
regulation and homeostasis, hormone responsive tumors, uteroplacental unit, and
embryogenesis (Auernhammer, et al., 2000)
I.5.2. Chemokine (C-C motif) ligand 2(CCL2):
CC chemokine ligand 2 (CCL2) or monocyte chemoattractant protein 1 (MCP-1) are part
of the CC chemokine family. They have a potent ability to stimulate migration of
monocytes, dendritic cells, natural killer (NK) cells, and memory T cells from blood to
the inflammation site (Deshmane, et al., 2009). Astrocytes, microglial cells, and neurons
are a source of CCL2 in brain. Expression of CCL2 in brain demonstrates highly
localized dispersion in several specific regions (Banisadr, et al., 2005).

I.6. Inductively coupled plasma mass spectrometry (ICP-MS):
Inductively coupled plasma mass spectrometry (ICP-MS) is an accurate quantification
method of cellular uptake of GNPs, because of its high specificity and low limits of
detection (18 parts per trillion for gold) (Alkilany, et al., 2009). ICP-MS detected 10 nm
GNPs in blood, spleen, liver, testis, lung, and brain of rats, 24 hours after injection with a
9

dose range of 10, 50, 100, and 250 nm GNPs (De Jong, et al., 2008). To determine
biodistribution of GNPs the target organs must be isolated, gold ions extracted and
oxidized via acid digestion, and then measured with ICP-MS (Cho, et al., 2009).
Interference of GNPs through the absorption of visible light should be accounted for
while conducting the above mentioned colorimetric assays or other assays that rely of
fluorescence changes (AshaRani, et al., 2009). Molecules from immediate region (i.e.
indicator dyes) are adsorbed by GNPs (Alkilany, et al., 2008) and result mask their
fluorescence (Willets and Van Duyne, 2007).

I.7. Blood Brain Barrier:
The blood–brain barrier (BBB) limits the passage of substances from the systemic
circulation into the CNS. Only passage of small high lipid soluble substances with the
molecular weight of 400-500 Da is allowed (Pardridge, 2003). It is crucial to verify that
GNPs pass the BBB and reach the neuronal tissue of CNS, if we are to look for uses of
GNP in the brain (Lasagna-Reeves, et al., 2010). Entrapment of nanoparticles (NPs) by
reticuloendothelial system (RES) impedes their delivery to the target organ. It should be
noted that the main interest for biological interfaces is in 1-100 nm diameter, and BBB
only allows passage of objects smaller than 12 nm (Oberdorster, et al., 2004; Sarin, et al.,
2008; Sonavane, et al., 2008). The amphipathic peptide conjugate improved the brain
delivery (without affecting the integrity of the BBB and cell viability); increasing the
10

concentration of gold by fourfold (while reducing its entrapment by spleen) (Guerrero, et
al., 2010).

Figure I.2: Three main sites of barriers in CNS: 1) Brain endothelium capillaries (forming BBB)
2) The arachnoid epithelium (middle layer of the meninges) 3) The choroid plexus epithelium
(secreting CSF). Tight junctions create a barrier and decrease permeability of paracellular
pathways. BBB is absent at circumventricular organs (CVO), specialized organs of
chemosensitivity and neurosecretion. CVOs are separated from the rest of the brain and CSF by
external glial barrier at the ependymal (Modified from Abbott, et al., 2006).
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Figure I.3: Transport pathways across the cerebrovascular endothelial cells: a) Paracellular
transport only allows diffusion of water soluble compounds due to strict restriction of tight
junction e.g. polar drugs b) Passive diffusion of lipid soluble amphiphilic agents e.g. alcohol c).
Transport protein (carriers) e.g. glucose, amino acids, choline, purine bases, and other substances
d). Receptor mediated transcytosis of certain proteins such as insulin and transferrin e).
Adsorptive endocytosis and transcytosis; cationization of native plasma proteins like albumin
facilitate their uptake (Modified from Abbott, et al. 2006).
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Circumventricular organs (CVO) and choroid plexus lack tight junctions and their blood
vessels are easily permeable; however, they are isolated by a similar epithelial formation.
Tight junctions of the ependymal cells, surrounding choroid plexus and CVOs limits
further diffusion of exogenous substances into brain. Choroid plexus produces CSF and
controls passages of majority of substances through its polarized epithelial. CVO
provides equilibrium between plasma and CSF. CVOs are divided into sensory and
secretory organs (Begley, 2004).

13

II. HYPOTHESIS AND SPECIFIC AIMS
Our central hypothesis is that citrate-capped spherical GNPs (10 nm) cross the BBB and
enters the CNS. To test this hypothesis the following experiments are performed.
• The primary set of experiments in this research project determines the optimal
concentration of phosphate buffered saline (PBS) that produces the least amount of
aggregation.
• The second set of experiments verifies the existence of 10 nm GNPs in the whole brain
24 hours after IV injection in C57BL/6 male mice.
• The third set of experiments is based on developing a novel method focused on
localization and bioaccumulation of GNPs in specific areas of CNS.
• The final set of experiments analyzes the pro-inflammatory cytokines expression in
different regions of brain.
The main purpose of the research is to localize and quantify GNPs in order to measure
the neuroinflammatory response in brain of the treated mice. The proposed work is
innovative, because there is little information on the transport of GNPs into CNS and the
brain’s inflammatory response.

14

II.1. Specific Aim1:
To determine the optimal buffer concentration of PBS for IV injection of GNPs
II.1.1. Method for Specific Aim1:
Aggregation of 200 µg mL-1 10 nm GNPs in various concentration of PBS (10 X, 1 X,
0.1 X, and 0.01 X) are measured via ultraviolet-visible spectroscopy.

II.2. Specific Aim 2:
To determine whether peripherally injected 10 nm citrate capped spherical GNP enters
the brain (quantification in whole brain)
II.2.1. Method for Specific Aim 2:
Inductively coupled plasma-mass spectrometry (ICP-MS) is utilized to detect distribution
and accumulation of GNPs 24 hours after IV injection in C57Bl/6 male mice.

II.3. Specific Aim 3:
After peripherally injection of GNPs, regions of the CNS that have the high concentration
of GNPs are identified (quantification and regional localization of GNPs in brain).
II.3.1. Method for Specific Aim 3:
Inductively coupled plasma-mass spectrometry (ICP-MS) is used to localize the
accumulation of GNPs 24 hours after IV injection in C57Bl/6 male mice. This is done by
examining different sections of brain tissue and spinal cord.

15

II.4. Specific Aim 4:
To verify the brain’s inflammatory response of C57Bl/6 male mice 24 hours after IV
injection of 10 nm GNPs
II.4.1. Method for Specific Aim 4:
Real-time PCR analyses of frozen brain regions are performed to verify mRNA
expressions of pro-inflammatory mediators (brain inflammation). A known inflammogen,
lipopolysaccharide (LPS 2 mg kg-1, SC) is used at this stage of experiment.
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III. MATERIALS AND METHODS
III.1. Synthesis and characterization of GNPs:
The 10 nm spherical GNP was synthesized using the citrate reduction method. GNP
particle sizes were analysed via UV-Vis absorption spectrophotometry and dynamic light
scattering analysis. Size and shape of GNPs were examined using transmission electrom
microscopy. Dr. Saber Hussain’s laboratory at Wright Patterson Air force (711
HPW/RHDJ, AFRL) synthesized the 200 µg mL-1 citrate-capped spherical 10 nm GNPs
throughout the project, and provided the following characterization analysis, data, and
graphs.
o

Figure III. 1: 200 µg mL-1 citrate-capped 10 nm
Spherical GNP

Figure III. 2: Transmission Electron Microscopy image of ~ 10 nm
GNPs synthesized using citrate reduction method.
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Figure III. 3: Dynamic Light Scattering Data for citrate-capped 10 nm spherical GNPs

Figure III.4: UV-Vis absorption spectrum of the citrate-capped 10 nm spherical GNPs
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Table1. Gold nanoparticle specifications

Method Used

Size

Morphology

Charge

Concentration

Citrate Reduction

~10 nm

Spheres

- 33.9 mV

200 µg mL-1

III.2. In Vitro Studies:
III.2.1. UV-Vis Absorption Spectrophotometry (UV-Vis):
In order to verify the optimum buffer concentration of PBS for IV injection of GNP, the
UV-Visible absorption measurements were carried out using Varian Cary 50 Bio
spectrophotometer. The instrument was set to the following parameters: 190-1100 nm
range, dual beam laser mode, 4800 nm min-1 scan rate, and 1 nm intervals. Double
deionized water was put into the cuvette as a baseline. Handling the cuvette by the clear
side it was checked for scratches. Then the clear side was gently wiped using a Kimwipe,
and the cuvette was put in the cuvette holder of the spectrometer with the clear side of it
facing the direction of the incident light. After sample preparation the 3 mL disposable
cuvettes were filled with the prepared samples to the mark. Finally the samples were put
into the cuvette and placed inside the spectrometer. All the measurements were done
using double deionized water as the baseline blank. When the run button was pressed the
wavelength scan on the computer monitor showed the recording of the absorbance
changes during the wavelength scan. This procedure was repeated for each sample.

19

III.2.2. Sample preparation:
400 µg mL-1 of 10 nm spherical GNPs was diluted to 200 µg mL-1 using double
deionized water. The synthesized GNPs were individually characterized by adding 0.30
mL of the 200 µg mL-1 GNP to 2.7 mL of double-deionized water. To obtain the ideal
buffer solution before IV injection, 0.270 mL of the 200 µg mL-1 10 nm GNP was added
to 0.03 mL of different concentrations of PBS 10 X, 1 X, 0.1 X, and 0.01 X (9:1 volume
ratio), and then diluted in the cuvette with 2.70 mL of double-deionized water.
Subsequently the sample was put into cuvette, and was run in UV-visible equipment.
Three control measurements were performed for 0.1X and 10.0X PBS (3.00 mL of PBS),
and for 180.00 µg mL-1 nanogold (0.270 mL of 200 µg mL-1 and 2.73 mL of doubledeionized water) individually.

Figure III.5: Cary 50 UV-Vis Absorption Spectrophotometer by Varian (Dr. Ioana Pavel
Sizemore’s Laboratory- Wright State University)
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III.3. In Vivo Studies:
III.3.1. Animals:
C57Bl/6 male mice were randomly divided into two groups: control and experimental.
The mice had free access to food and water and were maintained on a standard pellet diet
[Harlan/ Teklad 8640 Rodent Diet (54% carbohydrate, 29% protein, 17% fat), (Teklad
Animal Diets, USA)] and tap water ad libitum. Mice were housed under a 12 hour light
/12 hour dark cycle (6:30-18:30, lights on) at a controlled temperature 22 ± 2 °C. The
animals’ health was examined routinely. All protocols for research activities were
approved by Wright State University Laboratory Animal Care and Use Committee
(LACUC).

Figure III.6: C57Bl/6 Male Mice
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III.3.2. Intravenous Tail Vein Injection:
Mice were injected IV with GNPs via tail vein. To facilitate tail vein visualization and
ensure optimal injections, the tail vessels were dilated prior to injection. In order to
achieve vessel dilation, housing cages were put on heating pad and under the heating
lamp (60W) for about 10 minutes. Then, the mouse was restrained and transferred into a
restraining device. A 26 G needle was used for injection. After locating the vein, the
needle was inserted into the vein at an angle of approximately 20 degrees with its bevel
facing upward. The needle was inserted slowly near the distal end (tip) of the tail. The
needle was visualized as it enters the vein. Once the vein wall had been penetrated, the
needle’s angle was decreased and the needle was directed approximately 2 mm cranially.
Blood was aspirated into the needles’ hub just before injection. During material
administration the vein should blanch and no material and swelling should be detectable
at the injection site. Material was administered slowly to avoid vascular overload or
rupture of the vein from excess pressure. Pressure was applied over the injection site by
gently holding a piece of gauze over the injection site for approximately 30 seconds to
prevent hematoma formation. The needle was inserted midway into the vein down the
tail, permitting additional attempts for venipuncture proximally when the initial attempt
was unsuccessful.
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Figure III.7: Intravenous Injection of 10 nm Spherical GNPs to the Mouse

III.3.2.1. Experimental Groups:
 Treated group: 100 μl of 180 μg mL-110 nm spherical GNPs were intravenously injected
through the tail vein (the optimal volume for IV injection). In order to obtain a
physiological solution for IV injection, GNP suspension was diluted by adding one part
of 0.01 X PBS (10 µL) to nine parts of 200 μg mL-1 10 nm GNPs (90 µL).
 Control group: for intravenous injection of this group one part of 0.01 X (10 µL) was
added to nine parts of double deionized water (90 µL) to obtain a physiological solution.
III.3.3. Perfusion:
Perfusion after Euthanasia with Euthasol: 24 hours after IV injection of GNPs mice
were perfused. A 130 mg mL-1 Euthasol solution was used to euthanize the mice. Mice
were injected intraperitoneally (IP) with 1.25 µl g-1 of Euthasol (which corresponds to a
23

dose of 150 mg kg-1). Once unresponsive to tail pinch, the abdomen was opened and
thorax accessed through the diaphragm. A hypodermic needle was inserted into the left
ventricle and the heart’s right atrium was nicked. Slowly 30-40 mL PBS was pushed until
fluids draining from heart were clear. Then it was switched to a container of fixative, e.g.
a combination of formaldehyde (2%) and glutaraldehyde (2%) in phosphate buffer (pH
7.4) and was perfused~50 mL until the desired amount of fixative was reached.

Figure III.8: Mouse after Perfusion

Figure III.9: Brain tissue before and after
Perfusion

III.3.4. Collection of the Brain Tissue:
Immediately after perfusion whole brains (except brainstems) were collected and kept at 80°C.
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Figure III.10&III.11: Collecting the Brain Tissue after Perfusion

III.3.5. Brain Dissection:
Different regions of the CNS such as septum, caudate, hippocampus, hypothalamus,
cortex, frontal cortex, and spinal cord were dissected to specifically localize areas of
accumulated GNPs. Dissection was performed using 1mm brain block (Ted Pella) and
areas were selected by using stereotaxic atlas.
III.3.6. Digestion Protocol for Whole Brain:
The digestion process was performed using Explorer Hybrid pressurized microwave
digestion system. Microwave digestion with aqua regia is the preferred method for
digestion of mouse brain. In this experiment certain modifications of the digestion
protocol were needed to customize the protocol for brain tissue. This modification helped
improve the brain digestion process. For each control and treated brain tissue at least 4
vials were needed: 3 vials contained wet mass tissue sample (mg of brain) and 1 vial with
all reagents (= blank: no tissue). There were three reasons why spiked GNPs were
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omitted from ICP-MS quantification: first they cause saturation of the ICP-MS second
existence of a GNP standard reference which represented GNP in samples, and finally the
fact that the instrument measures the concentration of GNP three times (for each sample).
All vials were washed with 10% HNO3 and rinsed with double deionized water three
times. Prior to digestion, vials and samples were weighed. First the brain tissues were
homogenized manually with “Potter -Elvehjem homogenizer”, and the homogenate
tissues were transferred to the vials via double deionized water. Second 2 mL of 30%
aqua regia and 200 µl of 500 ppb of Rh (internal standard) were added to each vial. Then
vials were placed on the heat block at 60 ºC for 1 hour and 90 ºC for 3 hours
(predigestion). The vials were vented during heating with heating block or microwave (to
remove generated vapors). Subsequently Samples were placed in the heating microwave
and heated up to 120 ºC (table 2 and 3). 300-400 mL of H2O2 was added to each vial, and
heated till 150 ºC (table 4). Finally all samples were diluted to 10 mL. Brain tissue mass
and total volumes are very important for this experiment. Double deionized water was
added to the vials up to 10 g for whole brain (or 5 g for a specific area of the brain)
before performing the ICP-MS. Since all organic molecules were destroyed in digestion
process, there was no need to keep the vials cold before ICP-MS. Heating microwave
digestion was conducted by Ryan T. Saadawi in collaboration with University of
Cincinnati department of chemistry (Joseph A. Caruso Research Group).
The following table provides the digestion time and temperature setting:
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Table 2. First stage microwave digestion program

Temp

Ramp time

Hold time

Max pressure

Power

ºC

Min

Min

Bar

Watt

80
90

3
2

1:0
5

190
190

50
75

Power
Max
off
off

The vials are vent in this stage.

Table 3. Second stage microwave digestion program

Temp

Ramp time

Hold time

Max pressure

Power

ºC

Min

Min

Bar

Watt

90
110
120

3
2
10

1
1
5

190
190
190

50
50
75

Power
Max
off
off
off

*There should not be any visible chunks of tissue in the vial before adding H2o2 and proceeding to the
next step (table 4). Otherwise stage 1 and 2 of digestion program should be repeated one more time (H2o2
should only be added when the sample looks semi-clear).

Table 4. 3rd stage microwave digestion program

Temp

Ramp time

Hold time

`Max pressure

Power

ºC

Min

Min

Bar

Watt

100
130
150

3
2
2

1
1
3

190
190
190

80
75
75
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Power
Max
off
off
off

Figure III.12: Explorer Hybrid Pressurized Microwave Digestion System

Figure III.13& III.14: Observation of Chunk of Tissue after Digestion Prior to Modification

28

III.3.6.1. Aqua Regia Protocol:
Aqua regia or nitro-hydrochloric acid is a mixture of 3 part of concentrated hydrochloric
acid (HCl) to 1 part of concentrated nitric acid (HNO3). This mixture results in an
extremely corrosive solution which can dissolve even gold. In this experiment chemical
splash goggles, face shield, lab coat and appropriate gloves were worn. The solution was
mixed in a hood with the sash between me and the solution. First 150mL concentrated
HCl was poured in a polypropylene container. Then 50mL of concentrated HNO3 was
added to the HCl carefully and slowly. Afterwards for dilution few milliliters of this
mixture were added to water. It is very likely to become hot, more than 100 ºC. As a
result it should be handled with care. Aqua regia solutions should never be stored.
III.3.6.2. Modification and Optimization of Digestion Protocol:
To achieve the best result, several experiments were conducted and the results were
compared with each other. In predigestion step (before applying heating block), instead
of using aqua regia, different concentration of HNO3 was utilized. For this experiment the
optimal concentration was 35% (rather than using concentrated HNO3). After adding
35% HNO3 and Rh to the samples first and second stage of microwave digestion program
was performed (table 2 and 3). Then H2O2 was added at the third stage of microwave
digestion program (table 4) was run and finally concentrated HCl was added and again
first stage of microwave digestion program (table 2) was run. Ultimately a clear solution
without existence of any tissue in vials was developed.
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0.5 mL of 35% Nitric Acid was added to each sample plus 100μL of 500ppb Rh to each
sample. Vials were placed on the heat block at 60 ºC for 30 minutes, at 90 ºC for 30
minutes, and then at 110 C for 1 hour. Samples were placed in the heating microwave up
to 120 C. 100μL H2O2 was added and heated till 150 ºC. Then 0.75mL of 34% HCL was
added to all samples and heated to 90-100 ºC. Finally all samples are diluted to10.0 g (for
whole brain) or 5.0 g (for a specific area of the brain). Another modification performed to
make the result more reliable was omission of the third stage of microwave digestion
program (table 4) for the blank vials.

Figure III.15: Using Modified Protocol the Solutions Were Completely Clear after Digestion
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III.3.7. Inductively Coupled Plasma Mass Spectroscopy:
Inductively coupled plasma-mass spectrometry (ICP-MS) was utilized to quantify and
localize GNPs in the CNS. The instrument used is the Elmer Nexion 300D ICP-MS
(Waltham, MA).
8 µL of internal standard mix (Perkin Elmer) was added to each sample. Samples were
vortexed and placed in the auto-sampler. After conducting optimization of the instrument
to ensure accurate readings, 1 blank and 4 Gold standard solutions were read to obtain a
calibration curve. Samples were then run to obtain all concentrations of the digested
brain samples. The instrument was set to monitor metal 197Au.

Figure III.16: PerkinElmer® NexION® 300 D ICP-MS in WPAFB, 711 HPW/RHDJ,
AFRL (Reproduced with Permission from http://www.perkinelmer.com)
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III.3.8. Proinflammatory Cytokine Expression:
Mice were sacrificed, 24 hours after IV injection of 10 nm GNPs. Whole brains (except
brainstems) were collected and kept at -80°C.
Real-time PCR: Total RNA from several brain areas (Cortex, frontal cortex,
hippocampus, caudate, and hypothalamus) were isolated using Trizol® reagent
(Invitrogen) and Phase-lock heavy gel (Eppendorf AG, Hamburg, Germany). The RNA
was further cleaned using RNeasy mini spin column (Qiagen, Valencia, CA). Total RNA
(4 µg) were then be reverse-transcribed to cDNA using SuperScript™ III RNase H- and
oligo (dT)12-18 primers (Invitrogen) in a 20 µL reaction. Real-time PCR analysis of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Chemokine (C-C motif) ligand 2
(CCL-2), Interleukin-1 beta (IL-1β), Leukemia inhibitory factor (LIF), Interleukin-6(IL6), Tumor necrosis factor-alpha (TNF-α), and Oncostatin M (OSM) were performed in an
ABI 7500 sequence detection system (Applied Biosystems) in combination with
TaqMan® chemistry.

Specific primers and dual labeled internal fluorogenic (FAM

reporter dye, Taqman MGB Probe, nonfluorescent quencher) probe sets (TaqMan® Gene
Expression Assays) for these genes were procured from Applied Biosystems and used
according to the manufacturer’s recommendations.

All PCR amplifications (40-60

cycles) were performed in a total volume of 50 µL, containing 1 µL cDNA, 2.5 µL of the
specific Assay of Demand primer/probe mix and 25 µL of Taqman® Universal master
mix. Sequence detection software (version 1.7; Applied Biosystems) results were
exported as tab-delimited text files and imported into Microsoft Excel for further
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analysis.

Relative quantification of gene expression was performed using the

comparative threshold (CT) method as described by the manufacturer (Applied
Biosystems; User Bulletin 2). Changes in mRNA expression levels were calculated after
normalization to GAPDH. The ratios obtained after normalization were expressed as fold
change over corresponding saline-treated controls. Additionally, A known inflammogen,
lipopolysaccharide (LPS, 2 mg kg-1, SC), was tested as a supplement. Real time PCR was
conducted in collaboration with the Centers for Disease Control and Prevention by Dr.
James P. O'Callaghan at the Molecular Neurotoxicology Laboratory.

III.4. Data and Statistical Analysis:
All data are expressed as mean ± SEM. Data were analyzed using STATISTICA® 7.1
(StatSoft Inc., Tulsa, OK). T ANOVA or un-paired t-test was used. Significance was
achieved when p<0.05. All data was expressed as mean ± SEM. Data were expressed
as mean and standard deviation.
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IV. RESULTS
IV.1. In Vitro Studies:
IV.1.1. Optimal PBS Concentration for IV Injection of 10 nm GNPs:
In order to acquire an ideal physiological solution for IV injection of 10 nm GNPs,
different concentration of PBS (10 X, 1 X, 0.1 X, 0.01 X) were mixed with 200 µg mL-1
10 nm GNPs (9 to 1 part). The aggregation of GNPs with these solutions was measured
using UV-Visible Spectroscopy. 10 nm GNP in 0.01 X PBS had the least level of
aggregation. The result of this study showed that mixture of 10 nm GNP and 0.01 X PBS
was the most favorable physiological solution for IV injection. 0.01 X PBS and 10 nm
GNPs were used separately as controls to compare the aggregation of 10 nm GNPs with
different concentration of PBS by UV-visible Spectroscopy.

34

Absorbance/a.u.

0.5

GNP 200 ppm_Diluted
10 times

0.4
0.3
0.2
0.1
0
300

400

500

600

Wavelength

700

800

nm-1

Figure IV.1: Ultraviolet-visible (UV-Vis) absorption spectrum of the spherical GNPs containing
-1

200 µg mL of the spherical GNP that was diluted by 10 fold.
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Figure IV.2: UV-Vis absorption spectrum of the control 200 µg mL spherical GNP that was
diluted by 11.11 fold for measurement
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Figure IV.3: UV-Vis absorption spectra of the control 0.01 X and 10.0 X PBS
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Figure IV.4: UV-Vis absorption spectrum of the normal treatment using 200 µg mL of the
spherical GNPs and 0.01 X PBS
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Figure IV.5: UV-Vis absorption spectrum of varied treatment using 200 µg mL of the spherical
GNPs and 0.1 X PBS
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Figure IV.6: UV-Vis absorption spectrum of the varied treatment using 200 µg mL of the
spherical GNPs and 1.0 X PBS
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Figure IV.7: UV-Vis absorption spectrum of the varied treatment using 200 µg mL of the
spherical GNPs and 10.0 X PBS
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Figure IV.8: UV-Vis absorption spectra of the GNP and PBS controls, the normal treatment, and
the varied treatment solutions
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Figure IV.1 shows the characteristic UV-Vis spectrum of the GNP suspension of 200 µg
-1

-1

mL that was diluted 10 fold to a concentration of 20 µg L . This ensured that the GNP

concentrations in the samples did not exceed the detection range of the instrument. The
peak height of 0.44 a. u. corresponds to absorption at 525 nm. Figure IV.2 shows the
control spectrum of the GNP suspension that was prepared as it is in a typical injection
solution and then diluted by 11.11 folds to a concentration of 18.00 µg L-1. Figure IV.3
shows the control spectra of 0.01 X, and 10.0 X PBS. No absorption features were
observed in the spectra of 0.1 X and 10.0 X of the PBS control. Figures IV.4, IV.5, IV.6,
and IV.7 show the normal and varied treatments. All normal and varied treatment
solutions contained 0.03 mL of PBS, an overall 18.00 ppm concentration of GNPs and a
total volume of 3.0 mL in the cuvette. The normal treatment originally consisted of 0.3
mL solution with the same concentration and volume ration as in the actual 0.1 mL
injection that was administered to the mice specimen. The normal injection contained
0.01 X PBS that was diluted 100 fold in the cuvette for measurement. The varied
treatment contained 0.1 X PBS, 1.0 X PBS, 10.0 X PBS that were also diluted 100 fold in
the cuvette for spectrum collection.
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IV.2. In Vivo Studies:
IV.2.1. Biodistribution of GNPs in Whole Brain:
All procedures including injection, digestion, perfusion, and ICP-MS were combined to
investigate the entry of GNPs through the BBB. 90 µL of 200 µg mL-1 10 nm GNPs plus
10 µL of 0.01 X PBS was injected IV to the tail vein. 24 hours after IV injection mice
were perfused; then the brains were collected, weighed, and digested. The ICP-MS
results indicated that GNPs crossed the BBB, and were distributed throughout the brain.
Treated mice had significantly higher concentration of GNPs compared to control mice.
The ICP-MS measurements showed the control mice had the lowest concentration of
GNP in their brain. Although the control mice were injected with PBS and double
deionized water, this low concentration may be the incidental artifact or result of
widespread existence of GNP in the environment.
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Figure IV.9: Calibration Curve in ICP-MS for Whole Brain Samples. 1 blank and 4 Gold
standard solutions were read to obtain a calibration curve.

Table 5. Gold accumulation in whole brain after 24 hours IV injection of gold nanoparticle

Blank

ICP-MS
-1
Raw (µg l )
0.52

Control 1

-1

0.000520

ICP-MS
volume
5

Total Au
(µg)
0.00

ppm Conc. (µg
-1
Au g sample)
-----

STD
(µg)
0.021

0.52

0.000528

5

0.00

0.0096

0.008

Control 2

0.34

0.000344

5

0.00

0.0060

0.004

µg mL

Control 3

0.52

0.000520

5

0.00

0.0060

0.083

Treated 1

4.66

0.004658

5

0.02

0.0097

0.000

Treated 2

4.72

0.004720

5

0.02

0.0098

0.029

Treated 3

6.70

0.006700

5

0.03

0.0134

0.041
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Figure IV.10: Gold accumulation in whole brain 24 hours after IV injection of GNPs (10 nm).
Concentration of GNPs in treated mice was significantly high in comparison to the controls. Data
were analyzed using unpaired student t-test. Data are expressed as mean± SEM with 3 mice per
group. * P<0.05 vs. control.

IV.2.2. Localization of GNPs in Specific CNS Regions:
To specifically localize and quantify the bioaccumulation of GNPs in CNS, specific
areas of brain including septum, caudate, hippocampus, hypothalamus, cortex, frontal
cortex, and spinal cord were collected (24 hours after IV injection of GNP) and tested.
Subsequently areas were digested and the concentration of GNPs was quantified using
ICP-MS. The localization and bioaccumulation assay successfully established that
hypothalamus, hippocampus, and septum had the highest levels of GNPs (6.7, 6.2, and
4.6 µg Au g-1, respectively).
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Figure IV.11: ICP-MS calibration curve for brain regions. 1 blank and 4 Gold standard solutions
were read to obtain a calibration curve

Table 6. Gold accumulation in specific regions of brain 24 hours after IV injection of GNP

Hippocampus

ICP-MS Raw
-1
(µg L total)
29.77

Total Au
-1
(µg mL )
0.029770

Sample
Volume (mL)
5.0000

Total Au
(µg)
0.14885

ppm Conc. (µg
-1
Au g sample)
6.15

STD
(µg)
0.0034

Hypothalamus

16.26

0.016260

5.0000

0.0813

6.66

0.0008

Septum

11.58

0.011580

5.0000

0.0579

4.56

0.0005

Caudate

9.28

0.009280

5.0000

0.0464

1.95

0.0005

Frontal cortex

8.01

0.008010

5.0000

0.04005

1.51

0.0002

Spinal

6.79

0.006790

5.0000

0.03395

1.32

0.0004

Cortex

6.14

0.006140

5.0000

0.0307

0.64

0.0005

Blank 1

4.23

0.004230

5.0000

0.02115

-----

0.0001

Blank2

3.57

0.003570

5.0000

0.01785

-----

0.0001
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Figure IV.1IV2: Profile of gold concentrations in different regions of brain 24 hours after IV
injection of GNP (10 nm).

IV.2.3. CNS Inflammatory Response to GNPs:
Considering the extensive applications of GNPs, it is essential to investigate the harmful
neuroinflammatory effects of GNPs in specific regions of brain. Real-time PCR analysis
of frozen brain regions was utilized to evaluate brain inflammation by quantification of
pro-inflammatory mediators, LIF, CCL2 and IL1β. GNPs did not induce a significant
increase of cytokine/chemokine expression in hypothalamus, hippocampus, caudate,
cortex, or frontal cortex. LPS, as expected, caused a marked (100-fold) increase of the
same cytokines. Surprisingly, there was not any noticeable upregulation of cytokine
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expression (mRNA) in these areas, but there was a significant downregulation of IL-1β
expression in frontal cortex. Results revealed that GNPs enter brain and concentrate in
specific regions without eliciting an inflammatory response.
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Figure IV.13: LPS (2 mg kg-1 SC), as expected, caused a marked increase of the same cytokines.
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Figure IV.14: LPS (2 mg kg-1 SC), as expected, caused a marked increase of the same cytokines.
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Figure IV.15: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Interleukine-1 β
(IL-1 β) in hypothalamus did not indicate significant change of IL-1β level in the treated group.
Data were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.16: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Leukemia
inhibitory factor (Lif) in hypothalamus did not indicate significant change of Lif level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.17: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Chemokine (CC motif) ligand 2(CCL2) in hypothalamus did not indicate significant change of CCL2 level in
the treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.18: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Interleukine-1 β
(IL-1 β) in hippocampus did not indicate significant change of IL-1β level in the treated group.
Data were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.19: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Leukemia
inhibitory factor (Lif) in hippocampus did not indicate significant change of Lif level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.20: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Chemokine (CC motif) ligand 2(CCL2) in hippocampus did not indicate significant change of CCL2 level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.21: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Interleukine-1 β
(IL-1 β) in caudate did not indicate significant change of IL-1β level in the treated group. Data
were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.22: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Leukemia
inhibitory factor (Lif) in caudate did not indicate significant change of Lif level in the treated
group. Data were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.23: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Chemokine (CC motif) ligand 2(CCL2) in caudate did not indicate significant change of CCL2 level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.24: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Interleukine-1 β
(IL-1 β) in frontal cortex indicated significant change of IL-1β level in the treated group. Data
were analyzed using unpaired student t-test. Data are expressed as mean± SEM, ** P<0.01 vs.
control.
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Figure IV.25: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Leukemia
inhibitory factor (Lif) in frontal cortex did not indicate significant change of Lif level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.26: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Chemokine (CC motif) ligand 2(CCL2) in frontal cortex did not indicate significant change of CCL2 level in the
treated group. Data were analyzed using unpaired student t-test. Data are expressed as mean±
SEM.
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Figure IV.27: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Interleukine-1 β
(IL-1 β) in cortex did not indicate significant change of IL-1β level in the treated group. Data
were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.28: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Leukemia
inhibitory factor (Lif) in cortex did not indicate significant change of Lif level in the treated
group. Data were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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Figure IV.29: Mice were sacrificed, 24 hours after IV injection (GNP (10 nm) + PBS in treated
mice, and double deionized water + PBS in controls). Real-time PCR analysis of Chemokine (CC motif) ligand 2(CCL2) in cortex did not indicate significant change of CCL2 level in the treated
group. Data were analyzed using unpaired student t-test. Data are expressed as mean± SEM.
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V. DISCUSSIONS:
Initially, the optimal PBS concentration for IV injection of 10 nm spherical GNP was
verified using in vitro tests (10 nm GNP in 0.01 X PBS showed the least amount of
aggregation). Due to non-absorptive property of PBS, it did not cause any overlap or
interference with the gold spectrum. De Jong, et al. (2008) demonstrated that addition of
one part 10 X PBS to 9 part 10, 50, 100, and 250 nm GNP (1.0 X concentration of PBS)
caused agglomeration of GNP. Similarly, our results indicated PBS concentrations of
1.0 X and above (10.0 X) caused gradual aggregation of the GNPs. Increasing
concentration of PBS caused further aggregation of the GNPs (observed as a change in
the GNP peak profile). Notably in the case of the 10 X PBS modified treatment, the
GNP absorption peak became broader, the peak height decreased, and the wavelength
slightly shifted toward the longer wavelength through a shoulder around 650 nm. This
indicated a deformation of the spherical shape (perhaps change of the nanogold into
other metallic or ionic forms in the solution).
In order to utilize 10 nm GNPs in drug delivery, diagnosis, and treatment of CNS
diseases, it is essential to analyze its distribution, bioaccumulation, and neurotoxicity in
specific brain regions. De Jong et al. (2008) demonstrated that distribution of injected
GNPs is size dependent. His investigation proved 10 nm GNP had the most tissue
distribution (24 hour after IV injection). 10 nm GNP showed the highest concentration in
liver followed by blood, spleen, kidney, lungs, brain, reproductive organs, thymus, and
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heart. However, 50, 100, and 250 nm GNP were just distributed in liver, spleen, and
blood. Investigation of passage of GNP through the blood brain barrier and its entry to
the brain, proved the 10 nm spherical GNP (24 hours after IV injection) is capable of
passing the blood–brain barrier. The significant increase of GNP concentration in brain
of the treated group compared to control group is proportionate to the dose administered
and its biodistribution in different organs. Subsequently, to assess the bioaccumulation of
GNPs in specific regions of brain, different areas of brain were examined. Hypothalamus,
hippocampus, and septum had the highest levels of GNPs. This indicates the possibility
of passage of GNPs from choroid plexus and CVOs to the brain. Final investigation
measured the inflammatory response of GNPs in CNS. No significant increase of
proinflammatory cytokine/chemokine expressions were detected in the above mentioned
regions of brain. Interestingly the results revealed significant downregulation of IL-1β
expression in frontal cortex. The effect of GNP on IL-1β- dependent inflammatory
response is unclear. Sumbayev, et al. (2012) discovered the mechanism of suppression of
IL-1β-induced inflammatory reaction via citrate stabilized GNPs (in vivo and in vitro) for
the first time. Downregulation of IL-1β-induced inflammatory response indicated that IL1β molecules were accumulated near the surface of GNPs, which reduce the interaction
of IL-1β with interleukin receptors. Consequently, citrate stabilized GNPs revealed the
anti-inflammation response of IL-1β cytokines in a size dependent manner (5 nm GNP
having the strongest effect).
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Understanding the effects of NPs on the immune system is an essential step in accurate
evaluation of its risk assessment. Generalization of toxic effects of GNPs is difficult due
to influence of many factors such as chemical nature, size, roughness, form, aggregation
state, coating, etc. Substantial accumulation of citrate GNPs (10 nm) in dendritic cells did
not activate cell death. Results were measured in 4, 24, and 48 hour incubations. Further
assessment of cytokine secretion showed significant downregulation of IL-12 p70 (is
involved in T lymphocyte activation and regulation of antigen specific immune response)
and unaffected IL-6 secretion in presence of 10 nm citrate GNPs. These results revealed
that it is not possible to evaluate the effect of NPs in different organs by just measuring
their cytotoxicity. In brief, the implemented cytotoxic analysis is not sufficient for
determination of long term harmful effects of accumulation of GNPs in dendritic cells.
Consequently, further analyses are needed to determine the extent of alteration of the cell
functionality (Villiers, et al., 2010).
Although bulk gold is considered safe, biocompatibility and environmental impact of
GNPs must be investigated. Despite cell uptake and accumulation of spherical GNPs, the
MTT assay (mitochondrial activity) of the K562 cell line indicated no cytotoxicity up to
~ 100 μM. Due to toxicity of GNP precursors such as HAuCl4, its proper purification is
important. It should be noted that because of the interaction of cationic particles with
negatively charged cell membrane, they are toxic at much lower concentrations than their
anionic counterparts. Failure to find toxicity does not eliminate ability of GNPs to cause
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severe cellular damage i.e. 13 nm citrate capped GNP was not cytotoxic to skin cells, but
promoted formation of abnormal actin filament and diminished cell proliferation,
adhesion, and motility (Murphy, et al., 2008).
Proof of entry and accumulation of GNP in specific regions of brain raise the possibility
of usefulness of GNP in drug delivery and therapeutic treatment of CNS diseases.
Moreover, the discovery of anti-inflammatory effects of GNP will open a new window
for further therapeutic application of GNP in CNS and autoimmune disorders that are
reliant on specific cytokines specially IL-1β. However, it is essential to investigate the
long term effect of GNPs in different organs, and then the pathway of their clearance
from body.
Alteration of GNP surface area and charge are the main determinant of biokinetic fate of
GNPs in the organism. Biodistribution of GNP is highly dependent on its charge.
Accumulation of GNP in liver is size dependent (larger size having the highest
accumulation). Liver is the main organ for accumulation of positively charged GNPs and
kidney is the main organ of accumulation for negatively charged GNPs. Highly positive
charged NPs have the fastest elimination rate in liver (Hirn, et al., 2011). Most studied
nanoparticles are eliminated from circulatory system through reticuloendothelial system
(RES) and are eliminated in liver and spleen (Semmler-Behnke, et al. 2008). Exogenous
molecules and particles are taken up by resident macrophages of reticuloendothelial
system (called: kupffer cells in liver, microglia in brain, alveolar cells in lungs, and
reticular cells in lymph node, bone marrow, and spleen) (Abdelhalim, et al., 2011). In
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order for GNP to be eliminated through renal excretion, they must have hydrodynamic
diameter of 5.5 nm or smaller. Excretion of injected 18 nm GNP through hepatobiliary
system is only 0.5%, while renal excretion is extremely low (Semmler-Behnke, et al.
2008; Choi, et al., 2007).
Knowing nanoparticles are less prone to elimination routes, their elimination must be
studied very carefully (Ballou, et al., 2007). Because GNPs are mainly larger than 5.5
nm; their elimination from blood is mainly via reticuloendothelial system (RES).
Consequently, they are accumulated in liver and spleen (De Jong, et al., 2008 and von
Maltzahn, et al., 2009). Additional experiment and further studies are required to measure
the toxicity dose and potential toxicokinetic effect of various GNPs (different shape, size,
and surface charge) in different organs, especially in brain. Finally, it is imperative to
thoroughly investigate GNP biodistribution, long-term effects, clearance, and cytotoxicity
in brain and other vital organs before any clinical application.
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VI. CONCLUSION:
Initially we performed in vitro investigations, to determine the optimal buffer
concentration of GNPs for IV injection (10 nm GNP in 0.01 X PBS had the least level
of aggregation). Furthermore, GNPs in specific regions of brain were quantified and
localized. At the completion of this project, neuroinflammatory response of cytokines
was detected. Remarkably there was no upregulation of cytokines. On the contrary, IL1β in frontal cortex was significantly decreased, which is a sign of suppression of
inflammation. This effect is very important for the implication of GNPs in clinical
diagnosis and therapeutic treatment of neurodegenerative disorders and especially IL-1β
-dependent neuroimmune disorders.
This novel approach provides a basis for further utilization of GNPs in drug delivery,
detection, and therapeutic treatment of a number of CNS and neuroimmune diseases.
However to ensure its safety, there is need for extensive investigation on effective
dosage, duration of treatment, and on GNP clearance from the brain. Additionally, further
investigations are needed to assess the effects of different size, shape, charge, and
functionalized GNPs to improve their biomedical applications in chemical sensing,
biological imaging, drug delivery, treatment of neurodegenerative diseases, cancer
treatment, etc. Since this research is still in its early developmental stage, it is vital to
check the clearance, neuroinflammatory, and toxicity of various sizes and concentration
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of GNPs in a longer duration of treatment. Hopefully, this may provide the basis for
targeted treatment of diseases in future.
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